ABSTRACT The specific activities and percentage deficiencies of the glutamic oxaloacetic transaminase of erythrocytes (EGOT) were determined for patients with carpal tunnel syndrome (CTS) diagnosed by clinical examination and electrical conduction data; the EGOT data revealed a severe deficiency of vitamin B-6. After double-blind treatment with pyridoxine and placebo, two physicians identified those receiving pyridoxine (clinically improved) and those receiving placebo (did not improve) without error, P < 0.0078. Correcting a deficiency of the coenzyme at receptors of existing molecules of the apoenzyme appears to take place within days; correction of the deficiency in the number of molecules of the transaminase takes place over 10-12 weeks. The clinical response, appraised by the diminution of the symptoms of CTS, was correlated only with the restored levels of the transaminase which presumably results from a translational long-term increase in the number of molecules of EGOT by a mechanism activated by correcting a deficiency of pyridoxal 5'-phosphate. Apparent Km values of EGOT were identical for groups ofpatients with CTS and others without CTS but with identical specific activities, indicating that CTS is a primary deficiency of vitamin B-6 rather than one of a dependency state. Clinical improvement of the syndrome with pyridoxine therapy may frequently obviate hand surgery.
Folkers and co-workers (1, 2) initiated a study to detect and quantitate human deficiencies of vitamin B-6 by the determination of the specific activities and percentage deficiencies of the glutamic oxaloacetic transaminase of erythrocytes (EGOT). Ellis et al. (3) reported that a deficiency of vitamin B-6 existed in patients who had the carpal tunnel syndrome (CTS). Ellis et al. extended the EGOT data to show a severe deficiency of vitamin B-6 in 10 patients (4) and 11 more patients (5) . Comprehensive biochemical (6) and clinical studies (7) , including crossover treatment, with pyridoxine and placebo were conducted on the exemplary 22nd patient with CTS. For all patients receiving therapy with pyridoxine, the B-6 deficiency was corrected and the neurological syndrome was alleviated.
Becker and Granger (8) described CTS as a "common clinical entity," often associated with rheumatoid arthritis, obesity, myxedema, diabetes, pregnancy, and other conditions. "Rheumatic" conditions associated with this syndrome have included "tennis elbow," Dupuytren contracture, deQuervain disease, "trigger fingers," bursitis, and periarthritis of the shoulder.
From data on 1,215 patients with CTS at the Mayo Clinic between 1930 and 1960, Yamaguchi et al. (9) made the astounding observation that some patients had had the symptoms for up to 40 years. About 85% were more than 40 years old; 459 were surgically treated; 318 had associated systemic disease; 237 had other rheumatic conditions; only 660 appeared to have only CTS. The most common clinical findings were paresthesias, thenar muscle weakness and atrophy (which we now believe may result from many years of a severe deficiency of vitamin B-6), and positive Phalen and Tinel signs. When the compression of the median nerve in the carpal tunnel exists for many years, there may be a permanent sensory and motor loss. The synovium is involved, and the symptoms appear to result from tenosynovitis. Phalen (10) and Maxwell et al. (11) reviewed diseases associated with CTS. Tobin (12) and Sabour and Fadel (13) observed the syndrome in connection with pregnancy and use of the "pill. " Morelli and Sala (14) stated "the treatment . . . clearly must be surgical." Dolenc and Trontelj (15) asserted "microsurgery is a method ofchoice in the treatment ofpressure neuropathies. " Treatment by local injection or systemic administration ofcorticosteroids has been used. Surgery has been widely practiced, providing relief (16), often erratically, of limited duration, and no relief for up to 20% of those so treated.
For our 23rd to 29th patients, the EGOT data revealed a severe deficiency of vitamin B-6, and they were treated, in double-blind fashion, with pyridoxine and a placebo. Patients on placebo were treated with pyridoxine on a cross-over basis. The double-blind assessment was successful. The results are described herein.
DESIGN OF THE DOUBLE-BLIND TRIAL AND METHODS
A large population of patients exists in which symptoms of the fingers or hands or both are present. Some (4, 5) .
All seven patients had a significant deficiency of vitamin B-6. All seven had the typical CTS. The control EGOT data were made available to the physicians for patient selection. At the end of ca. 12 weeks, the physicians redetermined the clinical status of the patients and made a declaration as to whether a patient was being treated with pyridoxine or with a placebo. The commitments were correct. For this binomial distribution, P < 0.0078. Decoding revealed that four of the patients had received placebo and three had received pyridoxine. The four patients who had initially received the placebo were then treated with pyridoxine. The results ofthe open cross-over were as follows.
E. H., who had had symptoms for 3 yr, showed a complete biochemical response during days 111-113, a response (P < 0.01) of the pinch of the right hand during days 99-114, and a complete response (P < 0.001-0.01) by goniometer and pinch for both hands during days 123-160.
W.R., who had had symptoms for 8 yr, complied with the regimen only partially, as revealed by an incomplete biochemical response during days 403-438, but during this period there was a complete response (P < 0.001) by both goniometer and pinch for both hands. During days 48-267, only the right hand improved (P < 0.02-0.05).
F.C., who had had symptoms for 18 months, showed a complete biochemical response during days 187-288, but there were no differences between the measurements by the goniometer and for pinch for either hand in comparison with the control data. However, the score of symptoms had decreased from 42 to 15 (Table 1) .
A.L., who had symptoms for 10 yr, showed compliance by the EGOT data during days 143-144, and the measurements by goniometer showed significant improvement (P < 0.01) for both hands. The pinch values were unchanged even up to day 388.
For their declarations, the physicians were primarily guided by the objective measurements with the goniometer and the Preston pinch gauge. The scores in Table 1 include the subjective opinions of the patients on the presence and severity or the absence of such signs and symptoms and are less reliable than the objective measurements. The mean value ofthe total scores is 49 ± 9 (n = 7). The mean value of the total scores of those patients who received a placebo during the double-blind trial is 53 ± 10 (n = 4), a difference not statistically significant. The mean value ofthe scores for the three patients taking pyridoxine during the double-blind trial and for the four patients taking pyridoxine during the cross-over is 11 + 6 (n = 7). The difference between the mean values of the scores for control and the combined trials with pyridoxine is significant (P < 0.001).
The electromyographic data on five patients, obtained by two electrophysiologists, are in Table 3 . These data are in agreement with the clinical diagnosis of CTS for two patients, A. L. and M.B. Phalen (10) cautioned "One must remember, however, the carpal tunnel syndrome may be present with no evidence of electromyographic abnormalities." Melvin et al. (19) reported on the diagnostic specificity of motor and sensory conduction variables in the CTS and stated that "distal sensory latent periods were the most sensitive electrodiagnostic measurements for ascertaining the presence of carpal. tunnel syndrome." DISCUSSION Biochemical. The EGOT data on. the patients in the doubleblind' and cross-over trials agree with the data on the previous 22 patients (4-7). There has never been an exception to the association of this entrapment syndrome with a deficiency of vitamin B-6. A low SA (<0.20 -0.25).for EGOT is diagnostic of the severity of vitamin B-6 deficiency and of CTS.. SA is-more diagnostic than is. the percentage deficiency although both values have significance. The increase in SA from <0.20-0.25 to ca. 0.7 over ca. 10-12 weeks is unambiguously associated with clinical improvement. The differential enzymic analysis of EGOT is so precise that it may also show compliance or negligence on the part of a patient. in taking pyridoxine.
The increase in SA and the decrease in the symptoms were seldom decisive in ca. 6 weeks but were decisive in 10-12 weeks. This difference in time shows that-the increase in the number of molecules ofthe transaminase is a long-term change and is presumably based upon mechanisms of translational increase in the number ofmolecules ofEGOT. These mechanisms are activated by therapeutically correcting the deficiency of pyridoxal 5'-phosphate..
Merely correcting the deficiency of the coenzyme (pyridoxal 5'-phosphate) at the vacant receptors of the existing molecules of the apoenzyme appears to take place within' days, .but this correction has not been found to be associated with clinical improvement. The correction of a deficiency in the number of molecules of the transaminase, over 10-12 weeks, is associated with clinical improvement. Individuals may live for years with limited deficiencies of vitamin, B-6, but when the deficiency becomes sufficiently severe, paresthesia, stiffness, pain, etc. may be felt by the individual and reveal the presence of CTS to a physician. As the symptoms become unbearable, patients accept recommended orthopedic surgery of the hands.
There are two categories of vitamin deficiencies. A primary deficiency is caused by an inadequate level of the vitamin in the diet. A dependency state is caused by a biochemical abnormality due to a genetic defect. Homocystinuria (20) is said to be a dependency state of vitamin B-6. Dependency states are controlled by higher. doses than those required for a primary deficiency. Our study (6, 7) of patient 22, which showed that his CTS and vitamin B-6 deficiency were significantly improved, but not completely, by 2 mg of pyridoxine daily, the recommended daily allowance, indicated that the CTS is a primary deficiency. Shizukuishi et al. (22) compared the apparent Km values in the EGOT assays for a group ofeight patients with a severe' CTS and for a group of eight students; the mean SA values for the groups were identical; no significant difference was found for the apparent Kms.
Solomon and Hillman (23) studied the regulation of the metabolism of vitamin B-6 in human erythrocytes. The full induction of enzyme activity reflected the gradual replacement of circulating erythrocytes by newly formed cells with higher enzyme levels.
Clinical. The hand symptoms in patients with CTS are prominent because: (i) the physical use of hands accentuates symptoms; (ii) hands are important to human functions; and (iii) the symptoms are visible.
It is remarkable that patients having had such symptoms for years can show significant improvement on therapy with pyridoxine. W. R., who was 45 yr old, had had severe symptoms for 8 yr, but treatment with pyridoxine improved (P < 0.001) his hand performance by objective measurements. When, in the double-blind and .cross-over trials, W.R. and' A.L. had been treated with pyridoxine for 12 weeks, the strength and coor-. dination of the thenar muscles improved so that the tip of the thumb could be lifted and rotated medially to press the palm at the base of the little finger. A. L. had experienced increasing stiffness in hands for 10 yr, but the improvement after therapy with pyridoxine. was unambiguous and pronounced. Before treatment with pyridoxine, E.H. and A.C. could not hold a razor for shaving. Weakness and incoordination of finger movements prevented buttoning and unbuttoning ofclothing or normal use of a knife and fork. Frequently, the thumb and index and long fingers could not be opposed for writing with a pen or pencil.
If muscle' atrophy in the 'hands. were not prominent, as for E.H., T.G., A.C., W.R., and B.M:, the strength of pinch after therapy with pyridoxine was about tripled. The PIP joints of fingers before therapy with pyridoxine were invariably painful' on forced flexion. Hypoesthesia of the median nerve distribution was common. F.C. had severe hypoesthesia of the ulnar distribution; during the cross-over trial on pyridoxine-he appeared to improve subjectively but objective measurements were negative; The electrical conduction. studies indicated severe changes in ulnar nerves.
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